International Journal of Drug Regulatory Affairs (IJDRA)
  • Year: 2018
  • Volume: 6
  • Issue: 4

Integrating PLCM strategy in Pharmaceutical Emerging Market

  • Author:
  • Swagat Tripathy1,, Padala Narasimha Murthy2, Bibhu Prasad Patra3
  • Total Page Count: 12
  • Page Number: 21 to 32

1Aurobindo Pharma Limited, 313, Bachupally, Hyderabad, India

2Royal College Of Pharmacy And Health Sciences, Ganjam, Brahmapur, Odisha, India

3Xavier Institute of Management, Bhubaneswar, India

*Corresponding author Tel.: +91-8689992003 E-mail address: swagattripathy@ymail.com (Swagat Tripathy)

Online published on 17 September, 2019.

Abstract

All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in a way that the product is manifesting i.e. its mirror image with respect of sales. Ultimately increase of sustainable profit is the aim that every company aspires of the PLCM strategy. The understanding of a product‘s life cycle, can help a company to understand and realize when it is time to introduce and withdraw a product from a market, its position in the market compared to competitors, and the product‘s success or failure. This article details regarding Product Lifecycle Management in light of Pharmaceutical environment for the emerging markets (India, China, Russia, Brazil, and South Africa). Also an attempt has been made to compare PLCM of stated emerging countries with-highly regulated market (US).

Keywords

Product Lifecycle Management (PLCM), FDA, ANVISA, eCTD, CTD, ICH, Variation, CDER